In a trial in patients with metastatic breast cancer, the prognostic value of the number of circulating tumor cells (CTCs) at baseline was independent of tumor subtype, except in patients with HER2-positive disease treated with anti-HER2 targeted therapy. These data support the use of CTC detection as a tool contributing to personalized medicine.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Selective gene-expression profiling of migratory tumor cells in vivo predicts clinical outcome in breast cancer patients
Breast Cancer Research Open Access 31 October 2012
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Pantel, K., Alix-Panabieres, C. & Riethdorf, S. Cancer micrometastases. Nat. Rev. Clin. Oncol. 6, 339–351 (2009).
Cristofanilli, M. et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 351, 781–791 (2004).
Cristofanilli, M. et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J. Clin. Oncol. 23, 1420–1430 (2005).
Pantel, K. & Alix-Panabieres, C. Circulating tumor cells in cancer patients: challenges and perspectives. Trends Mol. Med. 16, 398–406 (2010).
Perou, C. M. et al. Molecular portraits of human breast tumors. Nature 406, 747–752 (2000).
Lehmann, B. D. et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest. 121, 2750–2767 (2011).
Sieuwerts, A. M. et al. Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J. Natl Cancer Inst. 101, 61–66 (2009).
Mostert, B. et al. Detection of circulating tumor cells in breast cancer may improve through enrichment with anti-CD146. Breast Cancer Res. Treat. 127, 33–41 (2010).
Giordano, A. et al. Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. Ann. Oncol. http://dx.doi.org/10.1093/annonc/mdr434.
Sieuwerts, A. M. et al. mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients. Clin. Cancer Res. 17, 3600–3618 (2011).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare that they receive grant support from Veridex, a Johnson & Johnson company.
Rights and permissions
About this article
Cite this article
Sleijfer, S., Foekens, J. Clinical value of circulating tumor cells in breast cancer. Nat Rev Clin Oncol 8, 696–698 (2011). https://doi.org/10.1038/nrclinonc.2011.167
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2011.167
This article is cited by
-
Selective gene-expression profiling of migratory tumor cells in vivo predicts clinical outcome in breast cancer patients
Breast Cancer Research (2012)